Annals of Laboratory Medicine

  • 제46권3호
  • /
  • Pages.241-243
  • /
  • 2026
  • /
  • 2234-3806(pISSN)
  • /
  • 2234-3814(eISSN)
대한진단검사의학회 (Korean Society for Laboratory Medicine)
권호 표지
DOI QR코드

DOI QR Code

Integrating Rapid Lymphoma Next-Generation Sequencing Panel-Based Testing into Routine Genomic Diagnostics

  • Saeam Shin (Department of Laboratory Medicine, Yonsei University College of Medicine) ;
  • Seung-Tae Lee (Department of Laboratory Medicine, Yonsei University College of Medicine)
  • 발행 : 2026.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720-48. https://doi.org/10.1038/s41375-022-01620-2
  2. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee. Blood 2022;140:1229-53. https://doi.org/10.1182/blood.2022015851
  3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: B-cell lymphomas. version 3.2026. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf (Accessed on 26th March 2026).
  4. de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 2022;140:2193-227. https://doi.org/10.1182/blood.2022015854
  5. Bastos-Oreiro M, Suárez-González J, Andrés-Zayas C, Carrión NC, Moreno S, Carbonell D, et al. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma. Sci Rep 2021;11:22815. https://doi.org/10.1038/s41598-021-02362-4
  6. Kim SJ, Kim JJ, Park MR, Park B, Ryu KJ, Yoon SE, et al. Feasibility of circulating tumor DNA detection in the cerebrospinal fluid of patients with central nervous system involvement in large B-cell lymphoma. Ann Lab Med 2025;45:90-5. https://doi.org/10.3343/alm.2024.0257
  7. Sujobert P, Le Bris Y, de Leval L, Gros A, Merlio JP, Pastoret C, et al. The need for a consensus next-generation sequencing panel for mature lymphoid malignancies. Hemasphere 2019;3:e169. https://doi.org/10.1097/HS9.0000000000000169
  8. Krigstein M, Jude E, Jaffrey A, Bye S, Wang B, Qiu MR, et al. Clinical validation of a rapid automated lymphoma next-generation sequencing panel. Ann Lab Med 2026;46:319-26. https://doi.org/10.3343/alm.2025.0254
  9. Yim J, Lee S, Kim S, Han B, Lim S, Song YK, et al. Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel. Blood Adv 2026;10:1929-42.
  10. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017;19:4-23. https://doi.org/10.1016/j.jmoldx.2016.10.002
  11. Blombery P. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. Leuk Lymphoma 2020;61:257-62. https://doi.org/10.1080/10428194.2019.1660974
  12. Julia E and Salles G. EZH2 inhibition by tazeme to stat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Future Oncol 2021;17:2127-40. https://doi.org/10.2217/fon-2020-1244